In addition, BVD-induced SNAI2 expression at the mRNA level was validated in primary NSCLC cells (PDX72) and a panel of NSCLC cell lines that have the KRAS mutation, e.g., H460, H2122, and H2030, but not in H838 cells, which does not possess aberrant RAS/RAF/MEK/ERK signaling (Figure 4C-D). Here, MAP2K7 is linked to non-small cell lung carcinoma.